For instance, Cialis (tadalafil) is marketed for erectile dysfunction, while Adcirca (also tadalafil) is used for pulmonary arterial hypertension. The rationale for dual branding includes unrelated ...

AgelessRx Introduces Tadalafil Daily in Continued Pursuit of Healthspan Innovation New offering delivers a clinician-directed option for patients seeking low-dose PDE5 inhibitor therapy AgelessRx ...

Some male enhancement, muscle-building, and mood-boosting supplements have been found to contain undisclosed prescription drugs like sildenafil (Viagra), tadalafil (Cialis), and even anti ...

Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

This side effect was most common in guys who took 10 to 20 milligrams of Cialis a day. Tadalafil Side Effects Long-Term There are no known long-term side effects of tadalafil.

The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes on hypertension, and how diagnosis time affects outcomes.

Before you consider buying from the black market, we’ll share some ways to find the lowest Cialis price and explain how this medication compares to similar drugs. We’ll also answer common ...

Ro Sparks distinguishes itself by combining the active ingredients found in two of the most popular FDA-approved ED medications: sildenafil (Viagra) and tadalafil (Cialis).

Tadalafil is sold by both as a generic and under the brand names of Cialis for erectile dysfunctin and Adcirca for PAH by Lilly. In PAH, tadalafils help to relax blood vessels, making it easier for ...

The FDA announced a recall of several over-the-counter sexual enhancement products containing undeclared prescription drugs like Viagra and Cialis.

The approval, which marks the first for a once-daily, single-tablet combination therapy for pulmonary arterial hypertension, is based on findings from the phase 3 A DUE study.